Highlights Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Market Closed - Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
0.2845 ^USD	+0.39%		-5.48%	-48.27%

04-16	Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	CI
04-08	Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft?	04-16	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
Qualigen Therapeutics, Inc. Enters into A Termination Agreement with Pan-RAS Holdings, Inc	03-28	CI
Qualigen Therapeutics, Inc. Enters into A License and Sublicense Agreement with Pan-RAS Holdings, Inc	02-22	CI
Qualigen Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Qualigen Therapeutics, Inc. Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors	11-07	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q2 Revenue $1.6M	15/08/23	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Qualigen Therapeutics Announces UD FDA IND Clearance to Initiate Phase 1 Clinical Trial of Qn-302 for Treatment of Advanced or Metastatic Solid Tumors	01/08/23	CI
Chembio Diagnostics, Inc. acquired FastPack® diagnostics business from Qualigen Therapeutics, Inc. for $5.8 million.	23/07/23	CI
Biosynex: acquisition of Qualigen in the United States	21/07/23	CF
Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology 2023 Annual Meeting	05/06/23	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Reports Q1 Revenue $1.6M	16/05/23	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
Earnings Flash (QLGN) QUALIGEN THERAPEUTICS Posts Q4 Revenue $5M	02/05/23	MT
Qualigen Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/05/23	CI
Qualigen Therapeutics Receives Nasdaq's Non-Compliance Notice	24/04/23	MT
Qualigen Therapeutics Says QN-302 US Patent Granted; Shares Rise	21/03/23	MT
Qualigen Therapeutics, Inc. to Present Five Posters At the American Association for Cancer Research Annual Meeting 2023	15/03/23	CI
Qualigen Therapeutics, Inc. Announces Publication of Key Data in the Peer-Reviewed Journal Molecules	08/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Qualigen Therapeutics, Inc.

Equities

QLGN

US74754R2022

Highlights

Filters